There remain many opportunities for determining combinatorial therapies for targeting or overcoming B7-H4-mediated T cell hypofunction in the tumor microenvironment can bring clinical benefit to patients with relative cancer risk. The gene discussed is VTCN1; the disease is neoplasm.